Record
Loading…
Record
Loading…
Viewing the record as of . Facts, events and changes are as the record holds them for that day. Back to today
organization
As of , Regeneron Pharmaceuticals was an American pharmaceutical company, headquartered in Tarrytown. Its CEO was Leonard S. Schleifer, since . It reported revenue of $14.20B for the period ended .
"sameAs": ["https://www.wikidata.org/wiki/Q7308054", "https://asof.is/record/regeneron-pharmaceuticals"],
"identifier": { "@type": "PropertyValue", "propertyID": "asof", "value": "ent_regeneron-pharmaceuticals" }| fact | value | valid fromThe day the value took effect, not the day it was published. A period figure (a year's revenue) is dated at the period's end.More in About → | confidenceHow well the sources support the value, from 0 to 1. A single primary source is asserted from 0.7; nothing below 0.5 is asserted; a dead or disagreeing source lowers it.More in About → | sourcesPrimary: the entity's own filing, feed or site. Secondary: a publisher reporting it. Each claim links every source it has, with the passage that states the value where one was read.More in About → |
|---|---|---|---|---|
| Chair | sec.gov: 1 source for Chair, claim clm_E84D1B159AB1 | |||
| Quarterly net income | $1.46B | sec.gov: 1 source for quarterly net income, claim clm_75B9586D5FEE | ||
| Quarterly operating income | $1.03B |
No dated events on the record yet.
Every claim on the timeline, including undated ones →| sec.gov: 1 source for quarterly operating income, claim clm_0F41A2F44A01 |
| Quarterly research and development | $1.48B | sec.gov: 1 source for quarterly research and development, claim clm_F00F9DA4362C |
|---|
| Quarterly revenue | $3.75B | sec.gov: 1 source for quarterly revenue, claim clm_471EC2DBAE0B |
|---|
| Research and development | $5.13B | sec.gov: 1 source for research and development, claim clm_C301E7CAF361 |
|---|
| Shares outstanding | 94.0M shares | sec.gov: 1 source for shares outstanding, claim clm_24C3500A1DEF |
|---|
| Total equity | $30.96B | sec.gov: 1 source for total equity, claim clm_CF9BA729AF1E |
|---|